Recombinant Human IL1RAP protein

**Background of IL1RAP Recombinant Protein**

Interleukin-1 receptor accessory protein (IL1RAP) is a critical co-receptor in the interleukin-1 (IL-1) signaling pathway, which plays a central role in regulating inflammatory and immune responses. As a member of the IL-1 receptor family, IL1RAP lacks intrinsic signaling capacity but is essential for forming functional receptor complexes with IL-1R1 or IL-1R2. Upon binding of IL-1 ligands (e.g., IL-1α, IL-1β), IL1RAP stabilizes the receptor-ligand interaction and facilitates downstream signaling via MyD88-dependent pathways, leading to NF-κB activation and pro-inflammatory cytokine production. Dysregulation of IL-1 signaling is implicated in autoimmune diseases, chronic inflammation, and cancer, making IL1RAP a potential therapeutic target.

Recombinant IL1RAP proteins are engineered using expression systems (e.g., mammalian, insect, or bacterial cells) to produce purified, bioactive forms of the protein. These recombinant variants often include specific domains, such as the extracellular region required for ligand-receptor binding, and may carry tags (e.g., Fc or His tags) for ease of purification and detection. They serve as valuable tools for studying IL-1 signaling mechanisms, screening inhibitors, or developing therapeutic strategies. For instance, IL1RAP-targeting antibodies or decoy receptors derived from recombinant IL1RAP are being explored to block pathogenic IL-1 signaling in conditions like rheumatoid arthritis or inflammatory bowel disease.

Additionally, IL1RAP has gained attention in oncology due to its overexpression on certain cancer cells and involvement in tumor microenvironment modulation. Recombinant IL1RAP proteins enable researchers to dissect its role in cancer progression or evaluate its potential as a biomarker. Overall, IL1RAP recombinant proteins bridge basic research and clinical applications, offering insights into inflammation-driven diseases and opportunities for targeted interventions.